Современные подходы к терапии послеоперационного макулярного отека

Закрыть метаданные

Послеоперационный макулярный отек, известный как синдром Ирвина—Гасса, является одной из вероятных причин снижения остроты зрения в глазной хирургии. В обзоре в обобщенном виде представлены данные литературы, касающиеся основных подходов к лечению данной патологии, рассматриваются основные группы препаратов, используемых для терапии послеоперационного макулярного отека.

Ключевые слова:

послеоперационный макулярный отек

нестероидные противовоспалительные средства

анти-VEGF

глюкокортикостероиды

Авторы:

Сакалова Е.Д.

ФГБНУ «Научно-исследовательский институт глазных болезней»

Даты поступления:

02.06.2020

Даты принятия в печать:

12.06.2020

Список литературы:

Gass JD, Norton EW. Fluorescein studies of patients with macular edema and papilledema following cataract extraction. Transactions of the American Ophthalmological Society. 1966;64:232-249. https://doi.org/10.1001/archopht.1966.03850010648005
Irvine AR. Cystoid maculopathy. Survey of Ophthalmology. 1976;21(1):1-17. https://doi.org/10.1016/0039-6257(76)90045-x
Shimura M, Yasuda K, Nakazawa T, Abe T, Shiono T, Iida T, Sakamoto T, Nishida K. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefe’s Archive for Clinical and Experimental Ophthalmology. 2009;247(12):1617-1624. https://doi.org/10.1007/s00417-009-1147-x
Bellocq D, Korobelnik J, Burillon,C, Voirin N, Dot C, Souied E, Conrath J, Milazzo S, Massin P, Baillif S, Kodjikian L. Effectiveness and safety of dexamethasone implants for post-surgical macular oedema including Irvine-Gass syndrome: the EPISODIC study. British Journal of Ophthalmology. 2015; 99(7):979-983. https://doi.org/10.1136/bjophthalmol-2014-306159
Catier A, Tadayoni R, Massin P, Gaudric A. Advantages of acetazolamide associated with anti-inflammatory medications in postoperative treatment of macular edema. Journal Francais d’Ophtalmologie. 2005;28(10):1027-1031. https://doi.org/10.1016/s0181-5512(05)81134-9
Benhamou N, Massin P, Haouchine B, Audren F, Tadayoni R, Gaudric A. Intravitreal triamcinolone for refractory pseudophakic macular edema. American Journal of Ophthalmology. 2003;135(2):246-249. https://doi.org/10.1016/s0002-9394(02)01938-4
Thach A, Dugel P, Flindall R, Sipperley J, Sneed S. A Comparison of Retrobulbar versus Sub-Tenon’s Corticosteroid Therapy for Cystoid Macular Edema Refractory to Topical Medications. Ophthalmology. 1997;104(12): 2003-2008. https://doi.org/10.1016/s0161-6420(97)30065-7
Randazzo A, Vinciguerra P. Chronic Macular Edema Medical Treatment in Irvine-Gass Syndrome: Case Report. European Journal of Ophthalmology. 2010;20(2):462-465. https://doi.org/10.1177/11206721100200023311
Williams G, Haller J, Kuppermann B, Blumenkranz MS, Weinberg DV, Chou C, Whitcup SM; Dexamethasone DDS Phase II Study Group. Dexamethasone Posterior-Segment Drug Delivery System in the Treatment of Macular Edema Resulting from Uveitis or Irvine-Gass Syndrome. American Journal of Ophthalmology. 2009;147(6):1048-1054.e2. https://doi.org/10.1016/j.ajo.2008.12.033
Barone A, Russo V, Prascina F, Delle Noci N. Short-term safety and efficacy of intravitreal bevacizumab for pseudophakic cystoid macular edema. Retina. 2009;29(1):33-37. https://doi.org/10.1097/iae.0b013e31818a1fbc
Spitzer M, Ziemssen F, Yoeruek E, Petermeier K, Aisenbrey S, Szurman P. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema. Journal of Cataract and Refractive Surgery. 2008; 34(1):70-75. https://doi.org/10.1016/j.jcrs.2007.08.021
Deuter C, Gelisken F, Stübiger N, Zierhut M, Doycheva D. Successful Treatment of Chronic Pseudophakic Macular Edema (Irvine-Gass Syndrome) with Interferon Alpha: A Report of Three Cases. Ocular Immunology and Inflammation. 2011;19(3):216-218. https://doi.org/10.3109/09273948.2011.562341
Jampol L. Pharmacologic Therapy of Aphakic Cystoid Macular Edema. Ophthalmology. 1982;89(8):891-897. https://doi.org/10.1016/s0161-6420(82)34699-0
Chin MS, Nagineni CN, Hooper LC, Detrick B, Hooks JJ. Cyclooxygenase-2 gene expression and regulation in human retinal pigment epithelial cells. Investigative Ophthalmology and Visual Science. 2001;42(10):2338-2346.
Cheng T, Cao W, Wen R, Steinberg RH, LaVail MM. Prostaglandin E2 induces vascular endothelial growth factor and basic fibroblast growth factor mRNA expression in cultured rat Muller cells. Investigative Ophthalmology and Visual Science. 1998;39:581-591.
Flach AJ. Nonsteroidal anti-inflammatory drugs. In: Tasman W, ed. Duane’s foundations of clinical ophthalmology. Philadelphia: Lippincott; 1994.
Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. International Ophthalmology Clinics. 2002;42(1):1-11. https://doi.org/10.1097/00004397-200201000-00003
Rossetti L, Chaudhuri J, Dickersin K. Medical prophylaxis and treatment of cystoid macular edema after cataract surgery. Ophthalmology. 1998;105(3): 397-405. https://doi.org/10.1016/s0161-6420(98)93018-4
Klein RM, Katzin HM, Yannuzzi LA. The Effect of indomethacin pretreatment on aphakic and pseudophakic cystoid macular edema. American Journal of Ophthalmology. 1979;87(4):487-489. https://doi.org/10.1016/0002-9394(79)90235-6
Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%. Clinical Ophthalmology. 2009;3:147-154. https://doi.org/10.2147/opth.s4684
Reiss A, Birnbaum F, Hansen L, Reinhard T. Successful treatment of cystoid macular edema with valdecoxib. Journal of Cataract and Refractive Surgery. 2007;33:682-685. https://doi.org/10.1016/j.jcrs.2007.06.060
Flach AJ, Jampol LM, Weinberg D, Kraff MC, Yannuzzi LA, Campo RV, Neumann AC, Cupples HP, Lefler WH, Pulido JS. Improvement in visual acuity in chronic aphakic and pseudophakic cystoids macular edema after treatment with topical 0.5% ketorolac tromethamine. American Journal of Ophthalmology. 1991;112(5);514-519. https://doi.org/10.1016/s0002-9394(14)76851-5
Heier J, Topping T, Baumann W, Dirks M, Chern S. Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema. Ophthalmology. 2000;107(11):2034-2038. https://doi.org/10.1016/s0161-6420(00)00365-1
Rho D. Treatment of acute pseudophakic cystoid macular edema: Diclofenac versus ketorolac. Journal of Cataract and Refractive Surgery. 2003;29(12): 2378-2384. https://doi.org/10.1016/s0886-3350(03)00233-5
Ke TL, Graff G, Spellman JM, Dirks MS, Chern S. Nepafenac, a unique nonsteroidal pro-drug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000;24(11):371-384. https://doi.org/10.1023/a:1007001131987
Shimazaki J, Saito H, Yang HY, Toda I, Fujishima H, Tsubota K. Persistent epithelial defect following penetrating keratoplasty: an adverse effect of diclofenac eyedrops. Cornea. 1995;14(6):623-627. https://doi.org/10.1097/00003226-199511000-00018
Giet M, Henkel C, Schuchardt M, Tolle M. Anti-VEGF Drugs in Eye Diseases: Local Therapy with Potential Systemic Effects. CPD Journal Acute Medicine. 2015;21(24):3548-3556. https://doi.org/10.2174/1381612821666150225120314
Рудько А.С., Эфендиева М.Х., Будзинская М.В, Карпилова М.А. Влияние фактора роста эндотелия сосудов на ангиогенез и гейрогенез. Вестник офтальмологии. 2017;133(3):75-81. https://doi.org/10.17116/oftalma2017133375-80
Nishijima K, Ng Y, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson S, Robinson G, Adamis A, Shima D. Vascular Endothelial Growth Factor-A Is a Survival Factor for Retinal Neurons and a Critical Neuroprotectant during the Adaptive Response to Ischemic Injury. The American Journal of Pathology. 2007;171(1):53-67. https://doi.org/10.2353/ajpath.2007.061237
Cervera E, Diaz-Llopis M, Udaondo P, Garcia S. Delpech Intravitreal pegaptanib sodium for refractory pseudophakic macular oedema. Eye (London, England). 2008;22(9):1180e2. https://doi.org/10.1038/eye.2008.2
Ratnoff OD. Increased vascular permeability induced by human plasmin. Journal of Experimental Medicine. 1965;122(5):905-921. https://doi.org/10.1084/jem.122.5.905
Penn J, Madan A, Caldwell R, Bartoli M, Caldwell R and Hartnett M. Vascular endothelial growth factor in eye disease. Progress in Retinal and Eye Research. 2008;27(4):331-371. https://doi.org/10.1016/j.preteyeres.2008.05.001
Querques G, Bux A, Martinelli D, Iaculli C, Noci N. Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmologica. 2009;87(6):623-630. https://doi.org/10.1111/j.1755-3768.2009.01580.x
Будзинская М.В., Погода Т.В., Генерозов Э.В., Чикун Е.А., Гурова И.В., Щеголева И.В., Сизова М.В. Современные фармакогенетические подходы к лечению возрастной макулярной дегенерации. Вестник офтальмологии. 2013;129(5):127-135.
Будзинская М.В., Шеланкова А.В., Андреева И.В., Нуриева Н.М. Результаты реальной клинической практики антиангиогенной терапии пациентов с макулярным отеком на фоне ретинальных венозных окклюзий. Точка Зрения. Восток—Запад. 2018;2:43-46. https://doi.org/10.25276/2410-1257-2018-2-43-46
Ferrara N, Gerber H and LeCouter J. The biology of VEGF and its receptors. Nature Medicine. 2003;9(6):669-676. https://doi.org/10.1038/nm0603-669
Tah V, Orlans HO, Hyer J, Casswell E, Din N, Sri Shanmuganathan V, Ramskold L, Pasu S. Anti-VEGF Therapy and the Retina: An Update. Journal of Ophthalmology. 2015;627674. https://doi.org/10.1155/2015/627674
Vinores SA, Youssri AI, Luna JD, Chen YS, Bhargave S, Vinores MA, Schoenfeld CL, Peng B, Chan CC, LaRochelle W, Green WR, Campochiaro PA. Upregulation of vascular endothelial growth factor in ischemic and nonischemic human and experimental retinal disease. Histology and histopathology. 1997;12(1):99-109.
Jain R, Stevens J, Bunce C, Garrett C, Hykin P. Ischaemic heart disease may predispose to pseudophakic cystoid macular oedema. Eye (London, England). 2001;15(1):34-38. https://doi.org/10.1038/eye.2001.9
Mason JO III, Albert MA Jr, Vail R. Intravitreal bevacizumab (Avastin) for refractory pseudophakic cystoid macular edema. Retina. 2006;26:356-357. https://doi.org/10.1097/00006982-200603000-00018
Arevalo J, Maia M, Garcia-Amaris R, Roca JA, Sanchez JG, Berrocal MH, Wu L; Pan-American Collaborative Retina Study Group. Intravitreal Bevacizumab for Refractory Pseudophakic Cystoid Macular Edema. Ophthalmology. 2009;116(8):1481-1487.e1. https://doi.org/10.1016/j.ophtha.2009.04.006
Staurenghi G, Lai T, Mitchell P, Wolf S, Wenzel A, Li J, Bhaumik A, Hykin PG; PROMETHEUS Study Group. Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes. Ophthalmology. 2018;125(6):850-862. https://doi.org/10.1016/j.ophtha.2017.12.002
Wittpenn J, Silverstein S, Heier J, Kenyon K, Hunkeler J, Earl M. A Randomized, Masked Comparison of Topical Ketorolac 0.4% Plus Steroid vs Steroid Alone in Low-Risk Cataract Surgery Patients. American Journal of Ophthalmology. 2008;146(4):554-560.e1. https://doi.org/10.1016/j.ajo.2008.04.036
Simone J, Whitacre M. Effects of anti-inflammatory drugs following cataract extraction. Current Opinion in Opthalmology. 2001;12(1):63-67. https://doi.org/10.1097/00055735-200102000-00011
Abe T, Hayasaka S, Nagaki Y, Kadoi C, Matsumoto M, Hayasaka Y. Pseudophakic cystoid macular edema treated with high-dose intravenous methylprednisolone. Journal of Cataract and Refractive Surgery. 1999;25(9):1286-1288. https://doi.org/10.1016/s0886-3350(99)00159-5
Asano S, Miyake K, Ota I, Sugita G, Kimura W, Sakka Y, Yabe N. Reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0,1% and betamethasone 0,1%. Journal of Cataract and Refractive Surgery. 2008;34(1):57-63. https://doi.org/10.1016/j.jcrs.2007.08.030
Bélair M, Kim S, Thorne J, Dunn JP, Kedhar SR, Brown DM, Jabs DA. Incidence of Cystoid Macular Edema after Cataract Surgery in Patients with and without Uveitis Using Optical Coherence Tomography. American Journal of Ophthalmology. 2009;148(1):128-135.e2. https://doi.org/10.1016/j.ajo.2009.02.029
Zhang X, Bao S, Lai D, Rapkins R, Gillies M. Intravitreal Triamcinolone Acetonide Inhibits Breakdown of the Blood-Retinal Barrier Through Differential Regulation of VEGF-A and Its Receptors in Early Diabetic Rat Retinas. Diabetes. 2008;57(4):1026-1033. https://doi.org/10.2337/db07-0982
Jonas J. Intravitreal Triamcinolone Acetonide: A Change in a Paradigm. Ophthalmic Research. 2006;38(4):218-245. https://doi.org/10.1159/000093796
Reichle M. Complications of intravitreal steroid injections. Optometry — Journal of the American Optometric Association. 2005;76(8):450-460. https://doi.org/10.1016/j.optm.2005.06.013
de Smet M. Corticosteroid Intravitreal Implants. New Treatments in Noninfectious Uveitis. 2012;51:36330.
Chang-Lin J, Attar M, Acheampong A, Robinson MR, Whitcup SM, Kuppermann BD, Welty D. Pharmacokinetics and Pharmacodynamics of a Sustained-Release Dexamethasone Intravitreal Implant. Investigative Opthalmology and Visual Science. 2011;52(1):80. https://doi.org/10.1167/iovs.10-5285
Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G; EFAL Study Group. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. Opthalmology. 2013;120(11): 2300-2309. https://doi.org/10.1111/j.1755-3768.2013.4461.x
Lowder C, Belfort RJr, Lightman S, Foster CS, Robinson MR, Schiffman RM, Li XY, Cui H, Whitcup SM; Ozurdex HURON Study Group. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Archives of Ophthalmology. 2011;129:545-553. https://doi.org/10.1001/archophthalmol.2010.339
Будзинская М.В., Мазурина Н.К., Егоров А.Е., Куроедов А.В., Лоскутов И.А., Плюхова А.А., Разик С., Рябцева А.А., Симонова С.В. Алгоритм ведения пациентов с ретинальными венозными окклюзиями. Сообщение 3. Неоваскулярные осложнения. Вестник офтальмологии. 2015;131(6):67-75. https://doi.org/10.17116/oftalma2015131667-75
Dutra Medeiros M, Navarro R, Garcia-Arumí J, Mateo C, Corcóstegui B. Dexamethasone Intravitreal Implant for Treatment of Patients With Recalcitrant Macular Edema Resulting From Irvine-Gass Syndrome. Investigative Opthalmology and Visual Science. 2013;54(5):3320. https://doi.org/10.1167/iovs.12-11463
Bellocq D, Pierre-Kahn V, Matonti F, Burillon C, Voirin N, Dot C, Akesbi J, Milazzo S, Baillif S, Soler V, Wolff B, Scemama C, Malclès A, Weber M, Kodjikian L. Effectiveness and safety of dexamethasone implants for postsurgical macular oedema including Irvine-Gass syndrome: the EPISODIC-2 study. British Journal of Ophthalmology. 2017;101(3):333-341. https://doi.org/10.1136/bjophthalmol-2016-308544
Farvardin M, Afarid M, Mehryar M, Hosseini H. Intravitreal infliximab for the treatment of sight-threatening chronic noninfectious uveitis. Retina. 2010;30(9):1530-1535. https://doi.org/10.1097/iae.0b013e3181d3758a
Wu L, Fernando Arevalo J, Hernandez-Bogantes E, Roca J. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. International Ophthalmology. 2012;32(3):235-243. https://doi.org/10.1007/s10792-012-9559-8
Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina. 2010;30(1):71-80. https://doi.org/10.1097/iae.0b013e3181bcef3b

Закрыть метаданные